Economic Evaluations of Anticancer Drugs Based on Medico-Administrative Databases: A Systematic Literature Review View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2020-02-14

AUTHORS

Elsa Bouée-Benhamiche, Philippe Jean Bousquet, Salah Ghabri

ABSTRACT

BackgroundOncology is among the most active therapeutic fields in terms of new drug development projects, with increasingly expensive drugs. The expected clinical benefit and cost effectiveness of these treatments in clinical practice have yet to be fully confirmed. Health medico-administrative databases may be useful for assessing the value of anticancer drugs with real-world data.ObjectiveThe objectives of our systematic literature review (SLR) were to analyse economic evaluations of anticancer drugs based on health medico-administrative databases, to assess the quality of these evaluations, and to identify the inputs from such databases that can be used in economic evaluations of anticancer drugs.MethodsWe performed an SLR by using PubMed and Web of Science articles published from January 2008 to January 2019. The search strategy focused on anticancer drug cost-effectiveness analyses (CEAs)/cost-utility analyses (CUAs) that were entirely based on medico-administrative databases. The review reported the main choices of economic evaluation methods in the analyses. The quality of the articles was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) and risk of bias assessment checklists.ResultsOf the 306 records identified in PubMed, 12 articles were selected, and one additional article was identified through Web of Science. Ten of the 13 articles were CEAs and three were CUAs. Most of the analyses were carried out in North America (n = 11). The economic metric used was the cost per life-year gained (n = 10) or cost per quality-adjusted life-year (n = 3). Reporting of the target analysis population and strategies in the articles was in agreement with the CHEERS guidelines. The structural assumptions underpinning the economic models displayed the poorest reporting quality among the items analysed. Representativeness bias (n = 11) and the issue of censored medical costs (n = 8) were the most frequently analysed risks.ConclusionA comparison of the economic results was not relevant due to the high heterogeneity of the selected studies. Our SLR highlighted the benefits and pitfalls related to the use of medico-administrative databases in the economic evaluations of anticancer drugs. More... »

PAGES

491-508

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40258-020-00562-z

DOI

http://dx.doi.org/10.1007/s40258-020-00562-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1124867534

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32056121


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Checklist", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Databases, Factual", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Models, Economic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality-Adjusted Life Years", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Health Data and Assessment, Survey Data Science and Assessment Division, French National Cancer Institute (Institut National du Cancer INCa), 52 Avenue Andr\u00e9 Morizet, 92100, Boulogne-Billancourt, France", 
          "id": "http://www.grid.ac/institutes/grid.455095.8", 
          "name": [
            "Department of Health Data and Assessment, Survey Data Science and Assessment Division, French National Cancer Institute (Institut National du Cancer INCa), 52 Avenue Andr\u00e9 Morizet, 92100, Boulogne-Billancourt, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bou\u00e9e-Benhamiche", 
        "givenName": "Elsa", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Health Data and Assessment, Survey Data Science and Assessment Division, French National Cancer Institute (Institut National du Cancer INCa), 52 Avenue Andr\u00e9 Morizet, 92100, Boulogne-Billancourt, France", 
          "id": "http://www.grid.ac/institutes/grid.455095.8", 
          "name": [
            "Department of Health Data and Assessment, Survey Data Science and Assessment Division, French National Cancer Institute (Institut National du Cancer INCa), 52 Avenue Andr\u00e9 Morizet, 92100, Boulogne-Billancourt, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bousquet", 
        "givenName": "Philippe Jean", 
        "id": "sg:person.016320413375.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016320413375.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Economic and Public Health Evaluation, French National Authority for Health (Haute Autorit\u00e9 de Sant\u00e9, HAS), 5 Avenue du Stade de France, 93218, Saint-Denis La Plaine CEDEX, France", 
          "id": "http://www.grid.ac/institutes/grid.457361.2", 
          "name": [
            "Department of Economic and Public Health Evaluation, French National Authority for Health (Haute Autorit\u00e9 de Sant\u00e9, HAS), 5 Avenue du Stade de France, 93218, Saint-Denis La Plaine CEDEX, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ghabri", 
        "givenName": "Salah", 
        "id": "sg:person.01276215131.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276215131.43"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.2165/11314110-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021346102", 
          "https://doi.org/10.2165/11314110-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12913-018-3080-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103149138", 
          "https://doi.org/10.1186/s12913-018-3080-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/2191-1991-3-21", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015691190", 
          "https://doi.org/10.1186/2191-1991-3-21"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40273-013-0109-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020308192", 
          "https://doi.org/10.1007/s40273-013-0109-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40273-018-0711-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106679621", 
          "https://doi.org/10.1007/s40273-018-0711-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12885-016-2482-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043250857", 
          "https://doi.org/10.1186/s12885-016-2482-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40258-018-0393-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104261461", 
          "https://doi.org/10.1007/s40258-018-0393-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10198-018-1024-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111160623", 
          "https://doi.org/10.1007/s10198-018-1024-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2407-14-586", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005873826", 
          "https://doi.org/10.1186/1471-2407-14-586"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1177/2168479014532259", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064086698", 
          "https://doi.org/10.1177/2168479014532259"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-02-14", 
    "datePublishedReg": "2020-02-14", 
    "description": "BackgroundOncology is among the most active therapeutic fields in terms of new drug development projects, with increasingly expensive drugs. The expected clinical benefit and cost effectiveness of these treatments in clinical practice have yet to be fully confirmed. Health medico-administrative databases may be useful for assessing the value of anticancer drugs with real-world data.ObjectiveThe objectives of our systematic literature review (SLR) were to analyse economic evaluations of anticancer drugs based on health medico-administrative databases, to assess the quality of these evaluations, and to identify the inputs from such databases that can be used in economic evaluations of anticancer drugs.MethodsWe performed an SLR by using PubMed and Web of Science articles published from January 2008 to January 2019. The search strategy focused on anticancer drug cost-effectiveness analyses (CEAs)/cost-utility analyses (CUAs) that were entirely based on medico-administrative databases. The review reported the main choices of economic evaluation methods in the analyses. The quality of the articles was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) and risk of bias assessment checklists.ResultsOf the 306 records identified in PubMed, 12 articles were selected, and one additional article was identified through Web of Science. Ten of the 13 articles were CEAs and three were CUAs. Most of the analyses were carried out in North America (n\u2009=\u200911). The economic metric used was the cost per life-year gained (n\u2009=\u200910) or cost per quality-adjusted life-year (n\u2009=\u20093). Reporting of the target analysis population and strategies in the articles was in agreement with the CHEERS guidelines. The structural assumptions underpinning the economic models displayed the poorest reporting quality among the items analysed. Representativeness bias (n\u2009=\u200911) and the issue of censored medical costs (n\u2009=\u20098) were the most frequently analysed risks.ConclusionA comparison of the economic results was not relevant due to the high heterogeneity of the selected studies. Our SLR highlighted the benefits and pitfalls related to the use of medico-administrative databases in the economic evaluations of anticancer drugs.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40258-020-00562-z", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1031175", 
        "issn": [
          "1175-5652", 
          "1179-1896"
        ], 
        "name": "Applied Health Economics and Health Policy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "keywords": [
      "Consolidated Health Economic Evaluation Reporting Standards", 
      "cost-effectiveness analysis", 
      "economic evaluation", 
      "economic evaluation methods", 
      "new drug development projects", 
      "economic model", 
      "medico-administrative database", 
      "economic results", 
      "CHEERS guidelines", 
      "economic metrics", 
      "poor reporting quality", 
      "utility analysis", 
      "representativeness bias", 
      "reporting standards", 
      "reporting quality", 
      "drug development projects", 
      "expensive drugs", 
      "structural assumptions", 
      "cost effectiveness", 
      "medical costs", 
      "anticancer drugs", 
      "main choice", 
      "systematic literature review", 
      "cost", 
      "Web of Science", 
      "clinical benefit", 
      "analysis population", 
      "development projects", 
      "real-world data", 
      "clinical practice", 
      "benefits", 
      "additional articles", 
      "literature review", 
      "article", 
      "assessment checklist", 
      "drugs", 
      "choice", 
      "PubMed", 
      "therapeutic field", 
      "evaluation method", 
      "high heterogeneity", 
      "heterogeneity", 
      "risk", 
      "assumption", 
      "review", 
      "search strategy", 
      "strategies", 
      "analysis", 
      "ResultsOf", 
      "database", 
      "evaluation", 
      "bias", 
      "America", 
      "issues", 
      "MethodsWe", 
      "quality", 
      "model", 
      "treatment", 
      "input", 
      "objective", 
      "terms", 
      "guidelines", 
      "checklist", 
      "standards", 
      "North America", 
      "data", 
      "population", 
      "project", 
      "values", 
      "items", 
      "records", 
      "CuA", 
      "study", 
      "science articles", 
      "pitfalls", 
      "effectiveness", 
      "results", 
      "Web", 
      "science", 
      "use", 
      "practice", 
      "metrics", 
      "agreement", 
      "comparison", 
      "such databases", 
      "method", 
      "field"
    ], 
    "name": "Economic Evaluations of Anticancer Drugs Based on Medico-Administrative Databases: A Systematic Literature Review", 
    "pagination": "491-508", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1124867534"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40258-020-00562-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32056121"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40258-020-00562-z", 
      "https://app.dimensions.ai/details/publication/pub.1124867534"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:37", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_857.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40258-020-00562-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40258-020-00562-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40258-020-00562-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40258-020-00562-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40258-020-00562-z'


 

This table displays all metadata directly associated to this object as RDF triples.

249 TRIPLES      22 PREDICATES      133 URIs      113 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40258-020-00562-z schema:about N0e2d34ab7d31460aaddae83131d2fb6a
2 N1004796a0098452697ecfb1798b8f91f
3 N1af81bfec917471ca2ffa9d49729ba1f
4 N24f0ebdf5b7d4597873cfb2855afb521
5 N2f1f2d02943b48b1a5d2bab15f578edc
6 N7055ff9cc312453f844a893df7d2131b
7 Nc663f884c5c147768ba729dc44451b58
8 Ndf756c7a05fa49438f08f2a55d5bf55b
9 Ne8f0e8c36a014d4bb68b75f36050f166
10 anzsrc-for:11
11 anzsrc-for:1117
12 anzsrc-for:14
13 anzsrc-for:1402
14 schema:author N9c704e40386246dca974b78ca1304e7f
15 schema:citation sg:pub.10.1007/s10198-018-1024-9
16 sg:pub.10.1007/s40258-018-0393-7
17 sg:pub.10.1007/s40273-013-0109-7
18 sg:pub.10.1007/s40273-018-0711-9
19 sg:pub.10.1177/2168479014532259
20 sg:pub.10.1186/1471-2407-14-586
21 sg:pub.10.1186/2191-1991-3-21
22 sg:pub.10.1186/s12885-016-2482-z
23 sg:pub.10.1186/s12913-018-3080-3
24 sg:pub.10.2165/11314110-000000000-00000
25 schema:datePublished 2020-02-14
26 schema:datePublishedReg 2020-02-14
27 schema:description BackgroundOncology is among the most active therapeutic fields in terms of new drug development projects, with increasingly expensive drugs. The expected clinical benefit and cost effectiveness of these treatments in clinical practice have yet to be fully confirmed. Health medico-administrative databases may be useful for assessing the value of anticancer drugs with real-world data.ObjectiveThe objectives of our systematic literature review (SLR) were to analyse economic evaluations of anticancer drugs based on health medico-administrative databases, to assess the quality of these evaluations, and to identify the inputs from such databases that can be used in economic evaluations of anticancer drugs.MethodsWe performed an SLR by using PubMed and Web of Science articles published from January 2008 to January 2019. The search strategy focused on anticancer drug cost-effectiveness analyses (CEAs)/cost-utility analyses (CUAs) that were entirely based on medico-administrative databases. The review reported the main choices of economic evaluation methods in the analyses. The quality of the articles was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) and risk of bias assessment checklists.ResultsOf the 306 records identified in PubMed, 12 articles were selected, and one additional article was identified through Web of Science. Ten of the 13 articles were CEAs and three were CUAs. Most of the analyses were carried out in North America (n = 11). The economic metric used was the cost per life-year gained (n = 10) or cost per quality-adjusted life-year (n = 3). Reporting of the target analysis population and strategies in the articles was in agreement with the CHEERS guidelines. The structural assumptions underpinning the economic models displayed the poorest reporting quality among the items analysed. Representativeness bias (n = 11) and the issue of censored medical costs (n = 8) were the most frequently analysed risks.ConclusionA comparison of the economic results was not relevant due to the high heterogeneity of the selected studies. Our SLR highlighted the benefits and pitfalls related to the use of medico-administrative databases in the economic evaluations of anticancer drugs.
28 schema:genre article
29 schema:inLanguage en
30 schema:isAccessibleForFree false
31 schema:isPartOf N32e552d7d0b04f4693f699f77fc1b901
32 Ne42e6241d19042f487aad51b713ebad7
33 sg:journal.1031175
34 schema:keywords America
35 CHEERS guidelines
36 Consolidated Health Economic Evaluation Reporting Standards
37 CuA
38 MethodsWe
39 North America
40 PubMed
41 ResultsOf
42 Web
43 Web of Science
44 additional articles
45 agreement
46 analysis
47 analysis population
48 anticancer drugs
49 article
50 assessment checklist
51 assumption
52 benefits
53 bias
54 checklist
55 choice
56 clinical benefit
57 clinical practice
58 comparison
59 cost
60 cost effectiveness
61 cost-effectiveness analysis
62 data
63 database
64 development projects
65 drug development projects
66 drugs
67 economic evaluation
68 economic evaluation methods
69 economic metrics
70 economic model
71 economic results
72 effectiveness
73 evaluation
74 evaluation method
75 expensive drugs
76 field
77 guidelines
78 heterogeneity
79 high heterogeneity
80 input
81 issues
82 items
83 literature review
84 main choice
85 medical costs
86 medico-administrative database
87 method
88 metrics
89 model
90 new drug development projects
91 objective
92 pitfalls
93 poor reporting quality
94 population
95 practice
96 project
97 quality
98 real-world data
99 records
100 reporting quality
101 reporting standards
102 representativeness bias
103 results
104 review
105 risk
106 science
107 science articles
108 search strategy
109 standards
110 strategies
111 structural assumptions
112 study
113 such databases
114 systematic literature review
115 terms
116 therapeutic field
117 treatment
118 use
119 utility analysis
120 values
121 schema:name Economic Evaluations of Anticancer Drugs Based on Medico-Administrative Databases: A Systematic Literature Review
122 schema:pagination 491-508
123 schema:productId N35f5ffea8ae641829bfbebfa0158539b
124 N651b00add6bc4db7b84201ad927c2e6a
125 N7208ed7428a34c6b85fa7eaf4998b06f
126 schema:sameAs https://app.dimensions.ai/details/publication/pub.1124867534
127 https://doi.org/10.1007/s40258-020-00562-z
128 schema:sdDatePublished 2022-05-20T07:37
129 schema:sdLicense https://scigraph.springernature.com/explorer/license/
130 schema:sdPublisher N6b528398ba2b4c618065990c417ffec1
131 schema:url https://doi.org/10.1007/s40258-020-00562-z
132 sgo:license sg:explorer/license/
133 sgo:sdDataset articles
134 rdf:type schema:ScholarlyArticle
135 N0e2d34ab7d31460aaddae83131d2fb6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Cost-Benefit Analysis
137 rdf:type schema:DefinedTerm
138 N1004796a0098452697ecfb1798b8f91f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Humans
140 rdf:type schema:DefinedTerm
141 N1af81bfec917471ca2ffa9d49729ba1f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Male
143 rdf:type schema:DefinedTerm
144 N24f0ebdf5b7d4597873cfb2855afb521 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Antineoplastic Agents
146 rdf:type schema:DefinedTerm
147 N2f1f2d02943b48b1a5d2bab15f578edc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Databases, Factual
149 rdf:type schema:DefinedTerm
150 N32e552d7d0b04f4693f699f77fc1b901 schema:issueNumber 4
151 rdf:type schema:PublicationIssue
152 N35f5ffea8ae641829bfbebfa0158539b schema:name doi
153 schema:value 10.1007/s40258-020-00562-z
154 rdf:type schema:PropertyValue
155 N651b00add6bc4db7b84201ad927c2e6a schema:name pubmed_id
156 schema:value 32056121
157 rdf:type schema:PropertyValue
158 N6b528398ba2b4c618065990c417ffec1 schema:name Springer Nature - SN SciGraph project
159 rdf:type schema:Organization
160 N7055ff9cc312453f844a893df7d2131b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Female
162 rdf:type schema:DefinedTerm
163 N7208ed7428a34c6b85fa7eaf4998b06f schema:name dimensions_id
164 schema:value pub.1124867534
165 rdf:type schema:PropertyValue
166 N78ac4778c41e4dffaf32920e26b3bc32 rdf:first sg:person.01276215131.43
167 rdf:rest rdf:nil
168 N9c704e40386246dca974b78ca1304e7f rdf:first Nd878112ad6904bcc8d8c8261ea97bd23
169 rdf:rest Nee1a745e5c56445b84f0ca20a6720dd2
170 Nc663f884c5c147768ba729dc44451b58 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Checklist
172 rdf:type schema:DefinedTerm
173 Nd878112ad6904bcc8d8c8261ea97bd23 schema:affiliation grid-institutes:grid.455095.8
174 schema:familyName Bouée-Benhamiche
175 schema:givenName Elsa
176 rdf:type schema:Person
177 Ndf756c7a05fa49438f08f2a55d5bf55b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Quality-Adjusted Life Years
179 rdf:type schema:DefinedTerm
180 Ne42e6241d19042f487aad51b713ebad7 schema:volumeNumber 18
181 rdf:type schema:PublicationVolume
182 Ne8f0e8c36a014d4bb68b75f36050f166 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Models, Economic
184 rdf:type schema:DefinedTerm
185 Nee1a745e5c56445b84f0ca20a6720dd2 rdf:first sg:person.016320413375.50
186 rdf:rest N78ac4778c41e4dffaf32920e26b3bc32
187 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
188 schema:name Medical and Health Sciences
189 rdf:type schema:DefinedTerm
190 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
191 schema:name Public Health and Health Services
192 rdf:type schema:DefinedTerm
193 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
194 schema:name Economics
195 rdf:type schema:DefinedTerm
196 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
197 schema:name Applied Economics
198 rdf:type schema:DefinedTerm
199 sg:journal.1031175 schema:issn 1175-5652
200 1179-1896
201 schema:name Applied Health Economics and Health Policy
202 schema:publisher Springer Nature
203 rdf:type schema:Periodical
204 sg:person.01276215131.43 schema:affiliation grid-institutes:grid.457361.2
205 schema:familyName Ghabri
206 schema:givenName Salah
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276215131.43
208 rdf:type schema:Person
209 sg:person.016320413375.50 schema:affiliation grid-institutes:grid.455095.8
210 schema:familyName Bousquet
211 schema:givenName Philippe Jean
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016320413375.50
213 rdf:type schema:Person
214 sg:pub.10.1007/s10198-018-1024-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111160623
215 https://doi.org/10.1007/s10198-018-1024-9
216 rdf:type schema:CreativeWork
217 sg:pub.10.1007/s40258-018-0393-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104261461
218 https://doi.org/10.1007/s40258-018-0393-7
219 rdf:type schema:CreativeWork
220 sg:pub.10.1007/s40273-013-0109-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020308192
221 https://doi.org/10.1007/s40273-013-0109-7
222 rdf:type schema:CreativeWork
223 sg:pub.10.1007/s40273-018-0711-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106679621
224 https://doi.org/10.1007/s40273-018-0711-9
225 rdf:type schema:CreativeWork
226 sg:pub.10.1177/2168479014532259 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064086698
227 https://doi.org/10.1177/2168479014532259
228 rdf:type schema:CreativeWork
229 sg:pub.10.1186/1471-2407-14-586 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005873826
230 https://doi.org/10.1186/1471-2407-14-586
231 rdf:type schema:CreativeWork
232 sg:pub.10.1186/2191-1991-3-21 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015691190
233 https://doi.org/10.1186/2191-1991-3-21
234 rdf:type schema:CreativeWork
235 sg:pub.10.1186/s12885-016-2482-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1043250857
236 https://doi.org/10.1186/s12885-016-2482-z
237 rdf:type schema:CreativeWork
238 sg:pub.10.1186/s12913-018-3080-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103149138
239 https://doi.org/10.1186/s12913-018-3080-3
240 rdf:type schema:CreativeWork
241 sg:pub.10.2165/11314110-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021346102
242 https://doi.org/10.2165/11314110-000000000-00000
243 rdf:type schema:CreativeWork
244 grid-institutes:grid.455095.8 schema:alternateName Department of Health Data and Assessment, Survey Data Science and Assessment Division, French National Cancer Institute (Institut National du Cancer INCa), 52 Avenue André Morizet, 92100, Boulogne-Billancourt, France
245 schema:name Department of Health Data and Assessment, Survey Data Science and Assessment Division, French National Cancer Institute (Institut National du Cancer INCa), 52 Avenue André Morizet, 92100, Boulogne-Billancourt, France
246 rdf:type schema:Organization
247 grid-institutes:grid.457361.2 schema:alternateName Department of Economic and Public Health Evaluation, French National Authority for Health (Haute Autorité de Santé, HAS), 5 Avenue du Stade de France, 93218, Saint-Denis La Plaine CEDEX, France
248 schema:name Department of Economic and Public Health Evaluation, French National Authority for Health (Haute Autorité de Santé, HAS), 5 Avenue du Stade de France, 93218, Saint-Denis La Plaine CEDEX, France
249 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...